Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International reported Q4 sales of $3.5 billion, a 10% increase, while full-year revenue reached $12.8 billion, up 10%. GAAP EPS for Q4 was $0.47 and adjusted EPS was $1.04, with full-year GAAP EPS at $2.53 and adjusted EPS at $3.61. The company's recent acquisition of Hillrom, effective Dec. 13, 2021, is projected to enhance top-line growth and innovation. Despite challenges from COVID-19, Baxter achieved significant growth across its product segments. The 2022 outlook projects reported sales growth of 24%-25% and adjusted earnings of $4.25-$4.35 per diluted share.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on April 1, 2022, to shareholders recorded by February 25, 2022. This brings the annual dividend rate to $1.12 per share. As a leading medtech company, Baxter continues to support patients and healthcare providers globally with innovative products across various medical sectors.
Baxter International Inc. (NYSE:BAX) will present at Citi's 2022 Virtual Healthcare Conference on February 23, 2022, at 1:15 p.m. Eastern Time. Chief Financial Officer Jay Saccaro is scheduled to deliver the presentation. A live webcast will be accessible at www.baxter.com and can be replayed until February 22, 2023.
Baxter provides crucial healthcare solutions, operating in over 100 countries for nearly 90 years. They focus on advancing innovative healthcare products and therapies.
Baxter International and the Thurgood Marshall College Fund have launched the Baxter HBCU STEM Scholars Program, a $3.5 million initiative aimed at supporting students from Historically Black Colleges and Universities (HBCUs) in STEM fields. The program will offer scholarships and mentorship to approximately 40 students over three years, addressing the low graduation rates among Black students (44% compared to 63% overall). The initiative also enhances teacher retention through mentorship for Black and Brown educators.
Baxter International Inc. (NYSE:BAX) will conduct a conference call on February 17, 2022, at 7:30 a.m. Central Time, to discuss its fourth-quarter 2021 financial results. Interested participants can pre-register via the provided link. This call will also be webcast on Baxter's website. Baxter provides a wide range of medical products and services in over 100 countries, focusing on critical care, kidney care, and surgical products. The company aims to leverage its legacy to drive innovation in healthcare.
Baxter International Inc. (NYSE:BAX) has completed its acquisition of Hillrom for $10.5 billion, paying $156 per share in cash. This transaction aims to enhance Baxter's healthcare transformation vision and is expected to generate approximately $250 million in annual pre-tax cost synergies by the end of year three. The acquisition is projected to positively impact Baxter's adjusted earnings per share, expanding margins and cash flow generation, with high single-digit returns on invested capital anticipated by year five. The combination will also enhance product accessibility globally.
Baxter International Inc. (NYSE:BAX) announced findings from a study suggesting that machine learning and AI can enhance medication safety in hospitals. Conducted with MedAware, the research analyzed over 3.8 million infusions and found that AI could assist in adjusting Dose Error Reduction Systems (DERS) to reduce medication errors. The results indicated that 52% of outliers triggered hard limits, showcasing the need for better DERS limits. The study was presented at the ASHP 2021 Midyear Clinical Meeting, highlighting advancements in infusion pump technology for patient safety.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on January 3, 2022, to shareholders recorded as of December 3, 2021. This dividend reflects an annual rate of $1.12 per share. The announcement emphasizes the company's commitment to returning value to its shareholders through consistent dividend payments.
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
